Pharmaceutical Aspects of Artificial Nutrition.
all-in-one parenteral admixture
artificial nutrition
compatibility
drug administration
drug admixing
enteral nutrition
parenteral nutrition
pharmaceutical expertise
stability
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
19 Nov 2019
19 Nov 2019
Historique:
received:
01
10
2019
revised:
11
11
2019
accepted:
15
11
2019
entrez:
23
11
2019
pubmed:
23
11
2019
medline:
23
11
2019
Statut:
epublish
Résumé
Artificial nutrition, including enteral (EN) and parenteral (PN) nutrition, is indicated whenever adequate oral nutrition fails to sufficiently supply the necessary nutrients to the body. It is a convenient, efficacious, safe, and well-tolerated form of clinical nutrition in the hospital and home setting. EN is administered via nasogastric tube or ostomies while PN usually requires a central venous access for administration, straight into the blood stream. The infused nutrients can then be taken up directly by the different organs. PN is targeted as a single daily portion formulated as an oil-in-water emulsion providing the necessary substrates for the catabolic and anabolic metabolism including macro- and micronutrients and fluids. PN has a complex pharmaceutical composition-all-in-one admixture-and its compounding or ready-to-use preparation. The use of PN is more challenging and more expensive compare to the use of EN, commercially available as ready-to-use formulations. EN and concomitant medication is highly challenging. Upon incorrect handling and administration, PN is associated with potentially severe or even fatal complications, mostly relating to the central venous access (e.g., catheter-related sepsis) or to a metabolic intolerance (e.g., hyperglycemia, refeeding syndrome) because of inappropriate administration. A correct order of admixing, correct dosing, and administration of the artificial is crucial for safety and efficacy; clinical and biochemical monitoring of the patient and treatment regimen adaption are necessary. The high number of reactive solutes allow only limited stability of a ready-to-use PN admixture. The potential for numerous incompatibilities and interactions renders PN admixtures generally unsuitable as drug vehicle. Laboratory compatibility and stability testing and pharmaceutical expertise are a prerequisite to define the PN composition including nutrients or even drugs admixed to define the appropriate and individualized nutrition and medication regimen. The aim of this narrative review is to present the actual state-of-the-art to deliver best quality artificial nutrition with special regard on pharmaceutical aspects such as instabilities, incompatibilities, and concomitant co-medication.
Identifiants
pubmed: 31752291
pii: jcm8112017
doi: 10.3390/jcm8112017
pmc: PMC6912726
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur J Pharm Sci. 2017 Jan 1;96:449-455
pubmed: 27742594
Nutr Clin Pract. 1996 Apr;11(2):59-65
pubmed: 8788339
J Clin Med. 2019 Jun 28;8(7):null
pubmed: 31261760
Br J Surg. 2003 Sep;90(9):1048-54
pubmed: 12945070
Nutr J. 2011 May 14;10:47
pubmed: 21569609
Nutrition. 2018 Mar;47:13-20
pubmed: 29429529
Diabetes Care. 2019 Jan;42(Suppl 1):S173-S181
pubmed: 30559241
JPEN J Parenter Enteral Nutr. 2000 Jan-Feb;24(1):37-41
pubmed: 10638470
Ger Med Sci. 2009 Nov 18;7:Doc19
pubmed: 20049083
J Pediatr Gastroenterol Nutr. 2007 Jan;44(1):71-6
pubmed: 17204957
JPEN J Parenter Enteral Nutr. 2003 Jul-Aug;27(4):291-9
pubmed: 12903895
Int J Med Sci. 2017 Sep 19;14(12):1213-1219
pubmed: 29104477
Nutrition. 1998 Sep;14(9):697-706
pubmed: 9760591
Cochrane Database Syst Rev. 2018 Jul 30;7:CD008462
pubmed: 30058070
Ann Pharmacother. 2000 Apr;34(4):440-5
pubmed: 10772427
JPEN J Parenter Enteral Nutr. 2014 Mar-Apr;38(3):296-333
pubmed: 24280129
Clin Nutr. 1998 Oct;17(5):223-6
pubmed: 10205342
Clin Exp Gastroenterol. 2018 Jul 10;11:255-264
pubmed: 30022846
Nutr Clin Pract. 2009 Dec;24(6):709-17
pubmed: 19955548
Dig Surg. 2018;35(5):442-447
pubmed: 29130989
Clin Nutr ESPEN. 2018 Feb;23:117-121
pubmed: 29460786
Int J Clin Pharm. 2018 Oct;40(5):1199-1208
pubmed: 30073611
Hosp Pharm. 1994 May;29(5):469-70, 473-5
pubmed: 10134172
J Pharm Anal. 2019 Apr;9(2):83-90
pubmed: 31011464
Am J Health Syst Pharm. 2012 Dec 15;69(24):2140-6
pubmed: 23230036
Clin Nutr. 2002 Dec;21(6):475-85
pubmed: 12468367
Clin Nutr. 2020 Jan;39(1):5-22
pubmed: 31255350
Ger Med Sci. 2009 Nov 18;7:Doc18
pubmed: 20049073
Eur J Gastroenterol Hepatol. 2018 Sep;30(9):997-1002
pubmed: 29738326
Clin Nutr. 2019 Mar 25;:null
pubmed: 30992207
J Clin Med Res. 2017 Apr;9(4):339-344
pubmed: 28270894
Nutr Clin Pract. 2016 Oct;31(5):596-609
pubmed: 27533942
Lancet. 1988 Mar 26;1(8587):700
pubmed: 2895223
Aliment Pharmacol Ther. 2018 Aug;48(4):410-422
pubmed: 29978597
Ann Pharmacother. 2003 Oct;37(10):1420-3
pubmed: 14519033
Lancet. 2013 Feb 2;381(9864):385-93
pubmed: 23218813
Curr Opin Clin Nutr Metab Care. 2005 May;8(3):291-5
pubmed: 15809532
Eur J Clin Nutr. 2014 Dec;68(12):1294-9
pubmed: 25248359
Int J Pharm. 2009 Mar 18;369(1-2):30-7
pubmed: 19027840
Bone Marrow Transplant. 2000 Mar;25(6):633-8
pubmed: 10734297
Clin Nutr. 2019 Feb;38(1):10-47
pubmed: 30005900
BMJ. 2011 Mar 18;342:d1447
pubmed: 21421667
J Clin Endocrinol Metab. 2012 Jan;97(1):16-38
pubmed: 22223765
Clin Nutr. 1996 Apr;15(2):53-9
pubmed: 16843998
Crit Care Med. 1999 Aug;27(8):1447-53
pubmed: 10470748
Clin Nutr. 2009 Aug;28(4):467-79
pubmed: 19464089
Nutrition. 1998 Feb;14(2):179-85
pubmed: 9530645
BMJ. 2003 Mar 29;326(7391):684
pubmed: 12663404
Am J Health Syst Pharm. 2008 Jan 1;65(1):73-80
pubmed: 18159044